{"ctNumber":"2023-506480-34-00","ctStatus":"Authorised","startDateEU":"2026-02-26","decisionDate":"2024-01-19T14:48:58.345","publishDate":"2026-10-14T03:34:17.569373051","ctPublicStatusCode":4,"authorizedApplication":{"authorizedPartI":{"id":146130,"rowSubjectCount":10,"rowCountriesInfo":[{"eutctId":100000000557,"name":"United States","isoNumber":840,"isoAlpha2Code":"US","isoAlpha3Code":"USA","current":true},{"eutctId":100000000556,"name":"United Kingdom","isoNumber":826,"isoAlpha2Code":"GB","isoAlpha3Code":"GBR","current":true}],"products":[{"id":610907,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10873488","productPharmForm":"SOLUTION FOR INFUSION","euMpNumber":"PRD10873488","prodAuthStatus":1,"prodName":"AAV9.LAMP2B","pharmForm":"SOLUTION FOR INFUSION","sponsorProductCode":"RP-A501","activeSubstanceName":"ADENO-ASSOCIATED VIRUS SEROTYPE 9 VECTOR CONTAINING THE HUMAN LAMP2 ISOFORM B TRANSGENE","euSubstNumber":"SUB316904","productOtherName":"Recombinant Adeno-associated virus serotype 9\nvector containing the human-lysosome-associated\nmembrane glycoprotein 2 isoform B transgene","nameOrg":"ROCKET PHARMACEUTICALS, INC","productSubstances":[{"productPk":"10873488","substancePk":"324593","nameOrg":"ROCKET PHARMACEUTICALS, INC","substanceOrigin":"Structurally Diverse Substance - Other","actSubstOrigin":"Structurally Diverse Substance - Other","actSubstName":"ADENO-ASSOCIATED VIRUS SEROTYPE 9 VECTOR CONTAINING THE HUMAN LAMP2 ISOFORM B TRANSGENE","substanceEvCode":"SUB316904","synonyms":["RP-A501","Recombinant adeno-associated virus serotype 9 vector containing the human-lysosome-associated membrane glycoprotein 2 isoform B transgene"]}],"atcCode":"A16AX","atcName":"VARIOUS ALIMENTARY TRACT AND METABOLISM PRODUCTS","atcTermLevel":"4","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":true,"orphanDrugDesigNumber":"EMA/OD/0000141142","doseUom":"Other","maxDailyDoseAmount":"67000000000000","doseUomTotal":"Other","maxTotalDoseAmount":"67000000000000","maxTreatmentPeriod":1,"timeUnitCode":"1","evCode":"PRD10873488","sponsorProductCodeEdit":"RP-A501","miaNumber":"108630F","therapies":[{"id":7904,"catReferenceNumber":"EMA/CAT/219514/2023","advancedTherapyType":"3","geneOfInterest":"LAMP2B","description":"Adeno-Associated Virus Serotype 9 (rAAV9) Vector","isGmo":false,"isInVivo":true,"geneTransferProductType":"3"}],"devices":[],"characteristics":["7","8"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":false,"productName":"AAV9.LAMP2B","jsonActiveSubstanceNames":"adeno-associated virus serotype 9 vector containing the human lamp2 isoform b transgene","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":610885,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10537MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"SIROLIMUS","pharmForm":"ORAL SOLUTION","activeSubstanceName":"SIROLIMUS","euSubstNumber":"SUB10537MIG","productSubstances":[{"substancePk":"144388","actSubstOrigin":"Chemical","actSubstName":"SIROLIMUS","substanceEvCode":"SUB10537MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/17/1910","doseUom":"mg milligram(s)","maxDailyDoseAmount":"2","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"2","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","scientificProductEvCode":"SUB10537MIG","devices":[],"characteristics":["4"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"SIROLIMUS","jsonActiveSubstanceNames":"sirolimus"},{"id":610904,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11336213","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD10347676","marketingAuthNumber":"EU/1/23/1727/001","prodAuthStatus":2,"prodName":"BEKEMV 300 mg concentrate for solution for infusion","pharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","activeSubstanceName":"ECULIZUMAB","euSubstNumber":"SUB25187","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/005652","nameOrg":"AMGEN TECHNOLOGY (IRELAND) UC","productSubstances":[{"productPk":"11336213","substancePk":"376568","nameOrg":"AMGEN TECHNOLOGY (IRELAND) UC","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"ECULIZUMAB","substanceEvCode":"SUB25187","synonyms":["ABP-959","H5G1.1"]}],"atcCode":"L04AA25","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"1200","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"1200","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Humanised monoclonal antibody","evCode":"PRD10347676","devices":[],"characteristics":["11"],"routes":["INTRAVENIOUS INFUSION"],"allSubstancesChemicals":false,"productName":"BEKEMV 300 mg concentrate for solution for infusion","jsonActiveSubstanceNames":"eculizumab","pharmaceuticalFormDisplay":"CONCENTRATE FOR SOLUTION FOR INFUSION"},{"id":610889,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10020MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PREDNISONE","pharmForm":"TABLET","activeSubstanceName":"PREDNISONE","euSubstNumber":"SUB10020MIG","productSubstances":[{"substancePk":"172490","actSubstOrigin":"Chemical","actSubstName":"PREDNISONE","substanceEvCode":"SUB10020MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"60","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"60","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Corticosteroid","scientificProductEvCode":"SUB10020MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"PREDNISONE","jsonActiveSubstanceNames":"prednisone"},{"id":610903,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB12570MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"RITUXIMAB","pharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","activeSubstanceName":"RITUXIMAB","euSubstNumber":"SUB12570MIG","productSubstances":[{"substancePk":"24724","actSubstOrigin":"-","actSubstName":"RITUXIMAB","substanceEvCode":"SUB12570MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/17/1869","doseUom":"mg/m2 milligram(s)/square meter","maxDailyDoseAmount":"750","doseUomTotal":"mg/m2 milligram(s)/square meter","maxTotalDoseAmount":"750","productChangedRelationMA":false,"maxTreatmentPeriod":2,"timeUnitCode":"2","scientificProductEvCode":"SUB12570MIG","devices":[],"characteristics":["4"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":false,"productName":"RITUXIMAB","jsonActiveSubstanceNames":"rituximab"},{"id":610901,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10020MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PREDNISONE","pharmForm":"TABLET","activeSubstanceName":"PREDNISONE","euSubstNumber":"SUB10020MIG","productSubstances":[{"substancePk":"173026","actSubstOrigin":"Chemical","actSubstName":"PREDNISONE","substanceEvCode":"SUB10020MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"60","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"60","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Corticosteroid","scientificProductEvCode":"SUB10020MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"PREDNISONE","jsonActiveSubstanceNames":"prednisone"},{"id":610890,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10020MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PREDNISONE","pharmForm":"TABLET","activeSubstanceName":"PREDNISONE","euSubstNumber":"SUB10020MIG","productSubstances":[{"substancePk":"43852","actSubstOrigin":"Chemical","actSubstName":"PREDNISONE","substanceEvCode":"SUB10020MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"60","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"60","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Corticosteroid","scientificProductEvCode":"SUB10020MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"PREDNISONE","jsonActiveSubstanceNames":"prednisone"},{"id":610894,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10020MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PREDNISONE","pharmForm":"TABLET","activeSubstanceName":"PREDNISONE","euSubstNumber":"SUB10020MIG","productSubstances":[{"substancePk":"266824","actSubstOrigin":"Chemical","actSubstName":"PREDNISONE","substanceEvCode":"SUB10020MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"60","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"60","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Corticosteroid","scientificProductEvCode":"SUB10020MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"PREDNISONE","jsonActiveSubstanceNames":"prednisone"},{"id":610886,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11582300","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD10444544","marketingAuthNumber":"EU/1/23/1735/001","prodAuthStatus":2,"prodName":"Epysqli 300 mg concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"ECULIZUMAB","euSubstNumber":"SUB25187","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/006036","nameOrg":"SAMSUNG BIOEPIS NL B.V.","productSubstances":[{"productPk":"11582300","substancePk":"376568","nameOrg":"SAMSUNG BIOEPIS NL B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"ECULIZUMAB","substanceEvCode":"SUB25187","synonyms":["ABP-959","H5G1.1"]}],"atcCode":"L04AA25","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"1200","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"1200","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Humanised monoclonal antibody","evCode":"PRD10444544","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS ADMINISTRATION"],"allSubstancesChemicals":false,"productName":"Epysqli 300 mg concentrate for solution for infusion","jsonActiveSubstanceNames":"eculizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":610898,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB14562MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"METHYLPREDNISOLONE SODIUM SUCCINATE","pharmForm":"POWDER FOR SOLUTION FOR INFUSION","activeSubstanceName":"METHYLPREDNISOLONE SODIUM SUCCINATE","euSubstNumber":"SUB14562MIG","productSubstances":[{"substancePk":"27047","actSubstOrigin":"-","actSubstName":"METHYLPREDNISOLONE SODIUM SUCCINATE","substanceEvCode":"SUB14562MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg/kg milligram(s)/kilogram","maxDailyDoseAmount":"0.8","doseUomTotal":"mg/kg milligram(s)/kilogram","maxTotalDoseAmount":"0.8","productChangedRelationMA":false,"maxTreatmentPeriod":4,"timeUnitCode":"2","otherMedicinalProduct":"Corticosteroid","scientificProductEvCode":"SUB14562MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"METHYLPREDNISOLONE SODIUM SUCCINATE","jsonActiveSubstanceNames":"methylprednisolone sodium succinate"},{"id":610888,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10537MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"SIROLIMUS","pharmForm":"COATED TABLET","activeSubstanceName":"SIROLIMUS","euSubstNumber":"SUB10537MIG","productSubstances":[{"substancePk":"233258","actSubstOrigin":"Chemical","actSubstName":"SIROLIMUS","substanceEvCode":"SUB10537MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/17/1910","doseUom":"mg milligram(s)","maxDailyDoseAmount":"2","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"2","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","scientificProductEvCode":"SUB10537MIG","devices":[],"characteristics":["4"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"SIROLIMUS","jsonActiveSubstanceNames":"sirolimus"},{"id":610895,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB12570MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"RITUXIMAB","pharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","activeSubstanceName":"RITUXIMAB","euSubstNumber":"SUB12570MIG","productSubstances":[{"substancePk":"24724","actSubstOrigin":"-","actSubstName":"RITUXIMAB","substanceEvCode":"SUB12570MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/17/1869","doseUom":"mg/m2 milligram(s)/square meter","maxDailyDoseAmount":"750","doseUomTotal":"mg/m2 milligram(s)/square meter","maxTotalDoseAmount":"750","productChangedRelationMA":false,"maxTreatmentPeriod":2,"timeUnitCode":"2","scientificProductEvCode":"SUB12570MIG","devices":[],"characteristics":["4"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":false,"productName":"RITUXIMAB","jsonActiveSubstanceNames":"rituximab"},{"id":610891,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11336214","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD10458812","marketingAuthNumber":"EU/1/23/1727/001","prodAuthStatus":2,"prodName":"BEKEMV 300 mg concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"ECULIZUMAB","euSubstNumber":"SUB25187","authorisationCountryCode":"NO","mrpNumber":"EMEA/H/C/005652","nameOrg":"AMGEN TECHNOLOGY (IRELAND) UC","productSubstances":[{"productPk":"11336214","substancePk":"376568","nameOrg":"AMGEN TECHNOLOGY (IRELAND) UC","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"ECULIZUMAB","substanceEvCode":"SUB25187","synonyms":["ABP-959","H5G1.1"]}],"atcCode":"L04AA25","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"1200","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"1200","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Humanised monoclonal antibody","evCode":"PRD10458812","devices":[],"characteristics":["11"],"routes":["INTRAVENIOUS INFUSION"],"allSubstancesChemicals":false,"productName":"BEKEMV 300 mg concentrate for solution for infusion","jsonActiveSubstanceNames":"eculizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":610906,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10020MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PREDNISONE","pharmForm":"TABLET","activeSubstanceName":"PREDNISONE","euSubstNumber":"SUB10020MIG","productSubstances":[{"substancePk":"287401","actSubstOrigin":"Chemical","actSubstName":"PREDNISONE","substanceEvCode":"SUB10020MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"60","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"60","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Corticosteroid","scientificProductEvCode":"SUB10020MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"PREDNISONE","jsonActiveSubstanceNames":"prednisone"},{"id":610905,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10537MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"SIROLIMUS","pharmForm":"COATED TABLET","activeSubstanceName":"SIROLIMUS","euSubstNumber":"SUB10537MIG","productSubstances":[{"substancePk":"144388","actSubstOrigin":"Chemical","actSubstName":"SIROLIMUS","substanceEvCode":"SUB10537MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/17/1910","doseUom":"mg milligram(s)","maxDailyDoseAmount":"2","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"2","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","scientificProductEvCode":"SUB10537MIG","devices":[],"characteristics":["4"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"SIROLIMUS","jsonActiveSubstanceNames":"sirolimus"},{"id":610902,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10537MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"SIROLIMUS","pharmForm":"COATED TABLET","activeSubstanceName":"SIROLIMUS","euSubstNumber":"SUB10537MIG","productSubstances":[{"substancePk":"233258","actSubstOrigin":"Chemical","actSubstName":"SIROLIMUS","substanceEvCode":"SUB10537MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/17/1910","doseUom":"mg milligram(s)","maxDailyDoseAmount":"2","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"2","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","scientificProductEvCode":"SUB10537MIG","devices":[],"characteristics":["4"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"SIROLIMUS","jsonActiveSubstanceNames":"sirolimus"},{"id":610893,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB01769MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"DIPHENHYDRAMINE HYDROCHLORIDE","pharmForm":"TABLET","activeSubstanceName":"DIPHENHYDRAMINE HYDROCHLORIDE","euSubstNumber":"SUB01769MIG","productSubstances":[{"substancePk":"27029","actSubstOrigin":"-","actSubstName":"DIPHENHYDRAMINE HYDROCHLORIDE","substanceEvCode":"SUB01769MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"50","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"50","productChangedRelationMA":false,"maxTreatmentPeriod":2,"timeUnitCode":"2","otherMedicinalProduct":"Substance of chemical origin","scientificProductEvCode":"SUB01769MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"DIPHENHYDRAMINE HYDROCHLORIDE","jsonActiveSubstanceNames":"diphenhydramine hydrochloride"},{"id":610887,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB09611MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PARACETAMOL","pharmForm":"TABLET","activeSubstanceName":"PARACETAMOL","euSubstNumber":"SUB09611MIG","productSubstances":[{"substancePk":"261177","actSubstOrigin":"Chemical","actSubstName":"PARACETAMOL","substanceEvCode":"SUB09611MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"g gram(s)","maxDailyDoseAmount":"1","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"1","productChangedRelationMA":false,"maxTreatmentPeriod":2,"timeUnitCode":"2","otherMedicinalProduct":"Substance of chemical origin","scientificProductEvCode":"SUB09611MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"PARACETAMOL","jsonActiveSubstanceNames":"paracetamol"},{"id":610900,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB25187","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"ECULIZUMAB","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"ECULIZUMAB","euSubstNumber":"SUB25187","productSubstances":[{"substancePk":"273378","actSubstOrigin":"Protein - Other","actSubstName":"ECULIZUMAB","substanceEvCode":"SUB25187"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/14/1304","doseUom":"mg milligram(s)","maxDailyDoseAmount":"1200","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"1200","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Humanised monoclonal antibody","scientificProductEvCode":"SUB25187","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":false,"productName":"ECULIZUMAB","jsonActiveSubstanceNames":"eculizumab"},{"id":610899,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB09611MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PARACETAMOL","pharmForm":"TABLET","activeSubstanceName":"PARACETAMOL","euSubstNumber":"SUB09611MIG","productSubstances":[{"substancePk":"119150","actSubstOrigin":"Chemical","actSubstName":"PARACETAMOL","substanceEvCode":"SUB09611MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"g gram(s)","maxDailyDoseAmount":"1","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"1","productChangedRelationMA":false,"maxTreatmentPeriod":2,"timeUnitCode":"2","otherMedicinalProduct":"Substance of chemical origin","scientificProductEvCode":"SUB09611MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"PARACETAMOL","jsonActiveSubstanceNames":"paracetamol"},{"id":610892,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB14562MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"METHYLPREDNISOLONE SODIUM SUCCINATE","pharmForm":"POWDER FOR SOLUTION FOR INFUSION","activeSubstanceName":"METHYLPREDNISOLONE SODIUM SUCCINATE","euSubstNumber":"SUB14562MIG","productSubstances":[{"substancePk":"27047","actSubstOrigin":"-","actSubstName":"METHYLPREDNISOLONE SODIUM SUCCINATE","substanceEvCode":"SUB14562MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg/kg milligram(s)/kilogram","maxDailyDoseAmount":"0.8","doseUomTotal":"mg/kg milligram(s)/kilogram","maxTotalDoseAmount":"0.8","productChangedRelationMA":false,"maxTreatmentPeriod":4,"timeUnitCode":"1","otherMedicinalProduct":"Corticosteroid","scientificProductEvCode":"SUB14562MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"METHYLPREDNISOLONE SODIUM SUCCINATE","jsonActiveSubstanceNames":"methylprednisolone sodium succinate"},{"id":610896,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11336212","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD10421748","marketingAuthNumber":"EU/1/23/1727/001","prodAuthStatus":2,"prodName":"BEKEMV 300 mg concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"ECULIZUMAB","euSubstNumber":"SUB25187","authorisationCountryCode":"IS","mrpNumber":"EMEA/H/C/005652","nameOrg":"AMGEN TECHNOLOGY (IRELAND) UC","productSubstances":[{"productPk":"11336212","substancePk":"376568","nameOrg":"AMGEN TECHNOLOGY (IRELAND) UC","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"ECULIZUMAB","substanceEvCode":"SUB25187","synonyms":["ABP-959","H5G1.1"]}],"atcCode":"L04AA25","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"1200","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"1200","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Humanised monoclonal antibody","evCode":"PRD10421748","devices":[],"characteristics":["11"],"routes":["INTRAVENIOUS INFUSION"],"allSubstancesChemicals":false,"productName":"BEKEMV 300 mg concentrate for solution for infusion","jsonActiveSubstanceNames":"eculizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":610897,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB01769MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"DIPHENHYDRAMINE HYDROCHLORIDE","pharmForm":"TABLET","activeSubstanceName":"DIPHENHYDRAMINE HYDROCHLORIDE","euSubstNumber":"SUB01769MIG","productSubstances":[{"substancePk":"172561","actSubstOrigin":"Chemical","actSubstName":"DIPHENHYDRAMINE HYDROCHLORIDE","substanceEvCode":"SUB01769MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"50","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"50","productChangedRelationMA":false,"maxTreatmentPeriod":2,"timeUnitCode":"2","otherMedicinalProduct":"Substance of chemical origin","scientificProductEvCode":"SUB01769MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"DIPHENHYDRAMINE HYDROCHLORIDE","jsonActiveSubstanceNames":"diphenhydramine hydrochloride"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"Gene Therapy for Danon Disease: A Phase 2 Study Evaluating the Efficacy and Safety of Intravenously Administered Adeno-Associated Virus Serotype 9 (rAAV9) Vector Containing the Human LAMP2 Isoform B Transgene (RP-A501; AAV9.LAMP2B) in Male Patients with Danon Disease","fullTitleTranslations":[{"id":12445500,"uuid":"be43bb90-89d3-4110-931b-6a538e9f14e9","attributeTranslation":"Terapia génica para la enfermedad de Danon: Estudio de fase II para evaluar la eficacia y la seguridad del vector de virus adenoasociado del serotipo 9 (rAAV9) administrado por vía intravenosa que contiene el transgén de la isoforma B de la proteína LAMP2 humana (RP-A501; AAV9.LAMP2B) en pacientes varones con enfermedad de Danon","language":7,"languageDescription":"Spanish"}],"publicTitle":"Multi-Center, Open Label Gene Therapy Study of RP-A501 in Male Patients with Danon Disease","publicTitleTranslations":[{"id":12445510,"uuid":"12a5fe9a-cd23-4db1-99f2-2f88aa690519","attributeTranslation":"Estudio abierto multicéntrico de RP-A501 en pacientes varones con enfermedad de Danon","language":7,"languageDescription":"Spanish"}],"shortTitle":"RP-A501-0123","secondaryIdentifyingNumbers":{"nctNumber":{"id":584927,"number":"NCT06092034"},"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"4","trialCategory":"2","justificationForTrialCategory":"This is a Phase II trial.","trialCategoryId":135374},"medicalCondition":{"partIMedicalConditions":[{"id":153354,"medicalCondition":"Danon Disease","medicalConditionTranslations":[{"id":12445487,"uuid":"4e202005-2687-4157-87b1-5a8368a70eed","attributeTranslation":"enfermedad de Danon","language":7,"languageDescription":"Spanish"}],"isConditionRareDisease":true}],"meddraConditionTerms":[{"termId":100000136961,"version":"20.0","level":"LLT","termName":"Danon disease","classificationCode":"10071756","organClass":10010331,"active":false}]},"trialObjective":{"trialScopes":[{"code":"3","trialScopeId":445038},{"code":"5","trialScopeId":445037},{"code":"4","trialScopeId":445036}],"mainObjective":"The primary objective of this study is to evaluate whether RP-A501 (an AAV9 capsid containing the LAMP2B transgene; AAV9.LAMP2B) will result in significant improvement as assessed via the primary endpoint comprised of LAMP2 myocardial tissue expression and LVMI.","mainObjectiveTranslations":[{"id":12445509,"uuid":"b46d3eb3-a162-4315-90d8-bc2e75f6f9db","attributeTranslation":"El objetivo principal de este estudio es evaluar si RP-A501 (una cápside de AAV9 que contiene el transgén LAMP2B: AAV9.LAMP2B) producirá una mejoría significativa evaluada mediante el criterio de valoración principal compuesto por la expresión tisular miocárdica de LAMP2 y el IMVI.","language":7,"languageDescription":"Spanish"}],"secondaryObjectives":[{"id":525081,"number":1,"secondaryObjective":"To assess the impact of RP-A501 on the components of the primary endpoint","secondaryObjectiveTranslations":[{"id":12445511,"uuid":"87b516af-fc56-4cae-ba9b-f2fe2fa6a025","attributeTranslation":"Los objetivos secundarios de este estudio son evaluar el impacto de RP-A501 en:\n1. Los componentes del criterio de valoración principal.","language":7,"languageDescription":"Spanish"}]},{"id":525082,"number":2,"secondaryObjective":"To assess the impact of RP-A501 on biomarker evidence of myocardial injury","secondaryObjectiveTranslations":[{"id":12445512,"uuid":"92fd5b86-2921-4f46-9c8c-c48cdd51f1f5","attributeTranslation":"2. Evidencia de biomarcadores de lesión miocárdica","language":7,"languageDescription":"Spanish"}]},{"id":525083,"number":3,"secondaryObjective":"To assess the impact of RP-A501 on quality of life and heart failure symptoms","secondaryObjectiveTranslations":[{"id":12445513,"uuid":"761f4a07-a26d-4d25-9138-0ac630319c86","attributeTranslation":"3. Calidad de vida y síntomas de insuficiencia cardíaca.","language":7,"languageDescription":"Spanish"}]},{"id":525084,"number":4,"secondaryObjective":"To assess the impact of RP-A501 on event-free survival","secondaryObjectiveTranslations":[{"id":12445514,"uuid":"f2184f65-8c38-4500-a832-7d7c61ade315","attributeTranslation":"4. Supervivencia sin acontecimientos.","language":7,"languageDescription":"Spanish"}]},{"id":525085,"number":5,"secondaryObjective":"To assess the impact of RP-A501 on safety","secondaryObjectiveTranslations":[{"id":12445515,"uuid":"b15453b9-0762-419d-82f9-177ffa856737","attributeTranslation":"5. Seguridad","language":7,"languageDescription":"Spanish"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":997583,"number":1,"principalInclusionCriteria":"Documentation of a pathogenic or likely pathogenic variant of the LAMP2 gene.","principalInclusionCriteriaTranslations":[{"id":12445501,"uuid":"36a4d670-9c44-4121-9d00-55f65985652a","attributeTranslation":"2.\tDocumentación de una variante patogénica o probablemente patogénica del gen LAMP2 por un laboratorio de pruebas genéticas que tenga la certificación CLIA.","language":7,"languageDescription":"Spanish"}]},{"id":997584,"number":2,"principalInclusionCriteria":"Male gender.","principalInclusionCriteriaTranslations":[{"id":12445502,"uuid":"d53621ca-7ea0-4f2d-b6bf-b02d333ae0ca","attributeTranslation":"3.\tSexo masculino.","language":7,"languageDescription":"Spanish"}]},{"id":997585,"number":3,"principalInclusionCriteria":"Age ≥8 years.","principalInclusionCriteriaTranslations":[{"id":12445503,"uuid":"0c860755-47db-4f70-b3e5-233151d04c1b","attributeTranslation":"4.\tEdad ≥8 años.","language":7,"languageDescription":"Spanish"}]},{"id":997586,"number":4,"principalInclusionCriteria":"Evidence of left ventricular hypertrophy with preserved systolic function phenotype as defined by each of the following: a. For subjects < 18 years, z-score of the left ventricular posterior wall or interventricular septum at end diastole ≥+ 2, and for subjects ≥18 years, left ventricular posterior wall or interventricular septum at end diastole >13 mm (>12 mm if family history of clinically significant Danon disease), b. Left ventricular ejection fraction (LVEF) ≥ 50%.","principalInclusionCriteriaTranslations":[{"id":12445504,"uuid":"4ce107ad-b65b-457c-9000-a45b83d01077","attributeTranslation":"5.\tEvidencia de hipertrofia del VI con función sistólica preservada, definida por cada uno de los siguientes factores:\na.\tPara participantes <18 años, puntuación z de la pared posterior del VI o del tabique interventricular al final de la diástole ≥ +2, y para participantes ≥18 años, grosor de la pared posterior del VI o del tabique interventricular al final de la diástole >13 mm (>12 mm si hay antecedentes familiares de enfermedad de Danon clínicamente significativa),\nb.\tFracción de eyección del ventrículo izquierdo (FEVI) ≥50 % .","language":7,"languageDescription":"Spanish"}]},{"id":997587,"number":5,"principalInclusionCriteria":"New York Heart Association (NYHA) Class II to III.","principalInclusionCriteriaTranslations":[{"id":12445505,"uuid":"c5acc2f1-184e-4fee-90f5-fe12366d1fa6","attributeTranslation":"6.\tClases II-III de la NYHA.","language":7,"languageDescription":"Spanish"}]},{"id":997588,"number":6,"principalInclusionCriteria":"hsTnI ≥20% above the ULN","principalInclusionCriteriaTranslations":[{"id":12445506,"uuid":"9b0ea391-7da9-46eb-9945-d277db261849","attributeTranslation":"7.\thsTnI ≥20 % por encima del LSN ≤12 meses antes de la visita de selección n.° 2.","language":7,"languageDescription":"Spanish"}]},{"id":997589,"number":7,"principalInclusionCriteria":"Ability to comply with study procedures including investigational therapy and follow-up evaluations.","principalInclusionCriteriaTranslations":[{"id":12445507,"uuid":"2265d15c-10a5-4b90-b47f-9f56613a81a0","attributeTranslation":"8.\tCapacidad para cumplir los procedimientos del estudio, incluido el PEI y las evaluaciones de seguimiento.","language":7,"languageDescription":"Spanish"}]},{"id":997590,"number":8,"principalInclusionCriteria":"Has received approved vaccination against Neisseria meningitidis ≥ 6 weeks before administration of RP-A501.","principalInclusionCriteriaTranslations":[{"id":12445508,"uuid":"060ce19c-b2de-4389-b55e-b350bcf1430a","attributeTranslation":"9.\tHa recibido la vacunación aprobada contra Neisseria meningitidis ≥6 semanas antes de la administración de RP-A501 (véanse los requisitos en el Plan de gestión de riesgos clínicos).","language":7,"languageDescription":"Spanish"}]}],"principalExclusionCriteria":[{"id":1702232,"number":1,"principalExclusionCriteria":"Anti-AAV9 neutralizing antibody titer >1:40.","principalExclusionCriteriaTranslations":[{"id":12445492,"uuid":"d1a4f75e-d861-4368-a93b-6be0dc4609af","attributeTranslation":"1.\tTítulo de anticuerpos neutralizantes anti-AAV9 >1:40.","language":7,"languageDescription":"Spanish"}]},{"id":1702233,"number":2,"principalExclusionCriteria":"Intravenous inotropic, vasodilator, or diuretic therapy within the 30 days prior to enrollment.","principalExclusionCriteriaTranslations":[{"id":12445493,"uuid":"e64f6277-ec26-4ff8-aa8f-fb17d996b546","attributeTranslation":"2.\tTratamiento inotrópico, vasodilatador o diurético intravenoso en los 30 días anteriores a la inscripción.","language":7,"languageDescription":"Spanish"}]},{"id":1702234,"number":3,"principalExclusionCriteria":"Presence or requirement for mechanical circulatory support (MCS).","principalExclusionCriteriaTranslations":[{"id":12445494,"uuid":"7f2c58e1-1d2c-44fe-bdda-28c23c35ed40","attributeTranslation":"3.\tPresencia o necesidad de soporte circulatorio mecánico (SCM).","language":7,"languageDescription":"Spanish"}]},{"id":1702235,"number":4,"principalExclusionCriteria":"Presence or requirement for mechanical ventilation.","principalExclusionCriteriaTranslations":[{"id":12445495,"uuid":"740becf6-bb08-46de-9166-992f65969a3a","attributeTranslation":"4.\tPresencia o necesidad de ventilación mecánica.","language":7,"languageDescription":"Spanish"}]},{"id":1702236,"number":5,"principalExclusionCriteria":"History of intracardiac thrombosis or arterial thromboembolic events including stroke, transient ischemic attack (TIA), acute coronary syndrome, myocardial infarction or unstable angina.","principalExclusionCriteriaTranslations":[{"id":12445496,"uuid":"f17e53b6-2822-49b6-8ff1-24d073f37a95","attributeTranslation":"5.\tAntecedentes de trombosis intracardíaca o acontecimientos tromboembólicos arteriales tales como ictus, accidente isquémico transitorio (AIT), síndrome coronario agudo, infarto de miocardio o angina inestable.","language":7,"languageDescription":"Spanish"}]},{"id":1702237,"number":6,"principalExclusionCriteria":"Prior cardiovascular (CV) surgery, percutaneous coronary intervention (PCI), or valvuloplasty.","principalExclusionCriteriaTranslations":[{"id":12445497,"uuid":"dec69856-fff9-4585-b6b0-65f8b634c8f1","attributeTranslation":"6.\tCirugía cardiovascular (CV), intervención coronaria percutánea (ICP) o valvuloplastia previas.","language":7,"languageDescription":"Spanish"}]},{"id":1702238,"number":7,"principalExclusionCriteria":"Greater than moderate valvular stenosis or regurgitation on most recent echocardiographic assessment.","principalExclusionCriteriaTranslations":[{"id":12445498,"uuid":"4f8ba067-7292-4988-a488-7f3e93742770","attributeTranslation":"7.\tEstenosis o insuficiencia valvular superior a un grado moderado en la evaluación ecocardiográfica más reciente.","language":7,"languageDescription":"Spanish"}]},{"id":1702239,"number":8,"principalExclusionCriteria":"Prior cardiac or other organ (lung, liver, other) transplantation.","principalExclusionCriteriaTranslations":[{"id":12445499,"uuid":"1e6fc947-af81-4859-b714-c66eee282ba0","attributeTranslation":"8.\tTrasplante cardíaco o de otro órgano (pulmón, hígado, otros) previo.","language":7,"languageDescription":"Spanish"}]}]},"endPoint":{"primaryEndPoints":[{"id":1166235,"number":1,"endPoint":"Primary endpoint including myocardial tissue expression of LAMP2 protein and decrease in left ventricular mass index (LVMI). Evaluation of efficacy associated with RP-A501.","isPrimary":true,"endPointTranslations":[{"id":12445488,"uuid":"f8e32721-ba0a-4cf3-9ab1-d9c876978dfe","attributeTranslation":"El criterio de valoración principal se define como sigue:\n1.\texpresión tisular miocárdica de la proteína LAMP2 en un grado ≥1 (mediante IHQ) Y\n2.\tdisminución ≥10 % del IMVI\nEl criterio de valoración principal se evaluará 12 meses después del tratamiento y se comparará con el valor inicial.","language":7,"languageDescription":"Spanish"}]}],"secondaryEndPoints":[{"id":1166236,"number":1,"endPoint":"LAMP2 protein expression, LVMI, hsTnI, NT-proBNP, KCCQ, and NYHA class. Evaluation of efficacy associated with RP-A501.","isPrimary":false,"endPointTranslations":[{"id":12445489,"uuid":"9f6dd08e-e84e-4755-aae2-9ce17ff68075","attributeTranslation":"Expresión tisular miocárdica de la proteína LAMP2, IMVI, hsTnI, NT-proBNP, KCCQ-12, clase de la NYHA.","language":7,"languageDescription":"Spanish"}]},{"id":1166237,"number":2,"endPoint":"Event free survival with events defined as death, heart transplant, mechanical circulatory support (MCS) or heart failure hospitalization. Evaluation of efficacy associated with RP-A501.","isPrimary":false,"endPointTranslations":[{"id":12445490,"uuid":"cae600c2-8686-4896-b05f-d2fa63126595","attributeTranslation":"Supervivencia sin acontecimientos, definidos los acontecimientos como muerte, trasplante de corazón, SCM u hospitalización por insuficiencia cardíaca desde la perfusión de RP-A501 hasta 60 meses después de la perfusión de RP-A501.","language":7,"languageDescription":"Spanish"}]},{"id":1166238,"number":3,"endPoint":"Incidence, severity and duration of treatment emergent safety events. Evaluation of safety.","isPrimary":false,"endPointTranslations":[{"id":12445491,"uuid":"f35cd197-e710-4496-b110-574566b6ab3d","attributeTranslation":"Incidencia, intensidad y duración de los acontecimientos de seguridad aparecidos con el tratamiento","language":7,"languageDescription":"Spanish"}]}]},"trialDuration":{"estimatedGlobalEndDate":"2029-10-31","estimatedEndDate":"2029-10-31","estimatedRecruitmentStartDate":"2024-04-01"},"sourceOfMonetarySupport":[],"populationOfTrialSubjects":{"ageRanges":[{"id":401965,"ageRangeCategoryCode":"4","ageRangeCategory":"4"},{"id":401963,"ageRangeCategoryCode":"2","ageRangeCategory":"2"},{"id":401964,"ageRangeCategoryCode":"3","ageRangeCategory":"3"}],"ageRangeSecondaryIds":[{"id":401968,"ageRangeCategoryCode":"2","ctAgeRangeCode":"5","ctAgeRange":"5","ageRangeCategory":"2"},{"id":401969,"ageRangeCategoryCode":"4","ctAgeRangeCode":"8","ctAgeRange":"8","ageRangeCategory":"4"},{"id":401967,"ageRangeCategoryCode":"4","ctAgeRangeCode":"7","ctAgeRange":"7","ageRangeCategory":"4"},{"id":401966,"ageRangeCategoryCode":"2","ctAgeRangeCode":"6","ctAgeRange":"6","ageRangeCategory":"2"}],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":false,"isMaleSubjects":true,"isVulnerablePopulationSelected":true},"individualParticipantData":{"planToShareIPD":"2"}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[{"id":64259,"competentAuthority":{"id":238287,"organisation":{"id":242068,"type":"EU Institution/Body/Agency","typeCode":"14","name":"European Medicines Agency","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100013412","organisationLocationStatus":"Active"},"address":{"addressId":253900,"oneLine":"Domenico Scarlattilaan 6","addressLine1":"Domenico Scarlattilaan 6","addressLine2":"","addressLine3":"","addressLine4":"","city":"Amsterdam","postcode":"1083 HS","country":2029,"countryName":"Netherlands"},"isBusinessKeyValidated":true,"businessKey":"ORG-100013412"}}],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","therapeuticAreas":[{"code":"16","name":"Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]"}],"medicalConditions":[{"id":153354,"medicalCondition":"Danon Disease","isConditionRareDisease":true}],"sponsors":[{"id":166742,"primary":true,"publicContacts":[{"id":492361,"type":"Public","functionalName":"Miriam Zeini Moreno","functionalEmailAddress":"mz@rocketpharma.com","telephone":"0034682675494","organisation":{"id":158712,"type":"Pharmaceutical company","typeCode":"10","name":"Rocket Pharmaceuticals Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100007461","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":492362,"type":"Scientific","functionalName":"Kinnari Patel","functionalEmailAddress":"kp@rocketpharma.com","telephone":"0034682675494","organisation":{"id":158712,"type":"Pharmaceutical company","typeCode":"10","name":"Rocket Pharmaceuticals Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100007461","organisationLocationStatus":"Active"}}],"thirdParties":[{"id":766406,"organisationAddress":{"id":225687,"organisation":{"id":229419,"type":"Pharmaceutical company","typeCode":"10","name":"Bioagilytix Labs LLC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100013030","organisationLocationStatus":"Active"},"address":{"addressId":240347,"oneLine":"2300 Englert Drive Suite G","addressLine1":"2300 Englert Drive Suite G","addressLine2":"","addressLine3":"","addressLine4":"","city":"Durham","postcode":"27713-4450","country":840,"countryName":"United States"},"phone":"+9193816097","email":"info@bioagilytix.com","isBusinessKeyValidated":true,"businessKey":"ORG-100013030"},"sponsorDuties":[{"id":1186379,"code":"4"}],"phoneNumber":"+9193816097","email":"info@bioagilytix.com"},{"id":766407,"organisationAddress":{"id":233827,"organisation":{"id":237590,"type":"Pharmaceutical company","typeCode":"10","name":"Fisher Bioservices Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100011655","organisationLocationStatus":"Active"},"address":{"addressId":249097,"oneLine":"4650 New Design Road Suite F","addressLine1":"4650 New Design Road Suite F","addressLine2":"","addressLine3":"","addressLine4":"","city":"Frederick","postcode":"21703-7522","country":840,"countryName":"United States"},"phone":"+12403381489","email":"FBSCustomer.Service@thermofisher.com","isBusinessKeyValidated":true,"businessKey":"ORG-100011655"},"sponsorDuties":[{"id":1186380,"code":"15","value":"Laboratory biorepository"}],"phoneNumber":"+12403381489","email":"FBSCustomer.Service@thermofisher.com"},{"id":766404,"organisationAddress":{"id":225699,"organisation":{"id":229431,"type":"Pharmaceutical company","typeCode":"10","name":"Eresearchtechnology Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100013039","organisationLocationStatus":"Active"},"address":{"addressId":240359,"oneLine":"1818 Market Street Ste 2600","addressLine1":"1818 Market Street Ste 2600","addressLine2":"","addressLine3":"","addressLine4":"","city":"Philadelphia","postcode":"19103-3600","country":840,"countryName":"United States"},"phone":"+12159720420","email":"customercare@clario.com","isBusinessKeyValidated":true,"businessKey":"ORG-100013039"},"sponsorDuties":[{"id":1186377,"code":"15","value":"Central Imaging"}],"phoneNumber":"+12159720420","email":"customercare@clario.com"},{"id":766403,"organisationAddress":{"id":233822,"organisation":{"id":237585,"type":"Pharmaceutical company","typeCode":"10","name":"Labcorp Central Laboratory Services S.a.r.l.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100011524","organisationLocationStatus":"Active"},"address":{"addressId":249092,"oneLine":"Rue Moise-Marcinhes 7","addressLine1":"Rue Moise-Marcinhes 7","addressLine2":"","addressLine3":"","addressLine4":"","city":"Meyrin","postcode":"1217","country":756,"countryName":"Switzerland"},"phone":"+41588227000","email":"jean-paul.lewest@labcorp.com","isBusinessKeyValidated":true,"businessKey":"ORG-100011524"},"sponsorDuties":[{"id":1186376,"code":"4"}],"phoneNumber":"+41588227000","email":"jean-paul.lewest@labcorp.com"},{"id":766408,"organisationAddress":{"id":234715,"organisation":{"id":238481,"type":"Pharmaceutical company","typeCode":"10","name":"CTI Clinical Trial and Consulting Services Europe GmbH","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100008276","organisationLocationStatus":"Active"},"address":{"addressId":250037,"oneLine":"Schillerstrasse 1/15, Weststadt","addressLine1":"Schillerstrasse 1/15","addressLine2":"Weststadt","addressLine3":"","addressLine4":"","city":"Ulm","postcode":"89077","country":2013,"countryName":"Germany"},"phone":"+497314000840","email":"regulatoryeurope@ctifacts.com","isBusinessKeyValidated":true,"businessKey":"ORG-100008276"},"sponsorDuties":[{"id":1186381,"code":"1"},{"id":1186382,"code":"10"},{"id":1186383,"code":"12"},{"id":1186384,"code":"5"},{"id":1186385,"code":"6"}],"phoneNumber":"+497314000840","email":"regulatoryeurope@ctifacts.com"},{"id":766402,"organisationAddress":{"id":233818,"organisation":{"id":237581,"type":"Pharmaceutical company","typeCode":"10","name":"Premier Research s.r.o.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100047985","organisationLocationStatus":"Active"},"address":{"addressId":249088,"oneLine":"Udernicka 5","addressLine1":"Udernicka 5","addressLine2":"","addressLine3":"","addressLine4":"","city":"Petrzalka","postcode":"851 01","country":2032,"countryName":"Slovakia"},"phone":"+421232161811","email":"premier-slovakia@premier-research.com","isBusinessKeyValidated":true,"businessKey":"ORG-100047985"},"sponsorDuties":[{"id":1186375,"code":"8"}],"phoneNumber":"+421232161811","email":"premier-slovakia@premier-research.com"},{"id":766405,"organisationAddress":{"id":225690,"organisation":{"id":229422,"type":"Pharmaceutical company","typeCode":"10","name":"Labcorp Early Development Laboratories Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100012865","organisationLocationStatus":"Active"},"address":{"addressId":240350,"oneLine":"671 South Meridian Road","addressLine1":"671 South Meridian Road","addressLine2":"","addressLine3":"","addressLine4":"","city":"Greenfield","postcode":"46140-8501","country":840,"countryName":"United States"},"phone":"+3174673700","email":"kimberly.cosky@labcorp.com","isBusinessKeyValidated":true,"businessKey":"ORG-100012865"},"sponsorDuties":[{"id":1186378,"code":"4"}],"phoneNumber":"+3174673700","email":"kimberly.cosky@labcorp.com"}],"organisation":{"id":158712,"type":"Pharmaceutical company","typeCode":"10","name":"Rocket Pharmaceuticals Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100007461","organisationLocationStatus":"Active"},"addresses":[{"id":155422,"organisation":{"id":158712,"type":"Pharmaceutical company","typeCode":"10","name":"Rocket Pharmaceuticals Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100007461","organisationLocationStatus":"Active"},"address":{"addressId":164170,"oneLine":"9 Cedarbrook Drive","addressLine1":"9 Cedarbrook Drive","addressLine2":"","addressLine3":"","addressLine4":"","city":"Cranbury","postcode":"08512-3618","country":840,"countryName":"United States"},"isBusinessKeyValidated":true,"businessKey":"LOC-100061380"}],"isCommercial":true,"commercial":"Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"This is a Phase II trial.","partOneTherapeuticAreas":[{"id":1259730,"therapeuticArea":{"code":"16","name":"Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]"}}],"productRoleGroupInfos":[{"id":452290,"comments":"SIROLIMUS, Epysqli 300 mg concentrate for solution for infusion, PARACETAMOL, SIROLIMUS, PREDNISONE, PREDNISONE, BEKEMV 300 mg concentrate for solution for infusion, METHYLPREDNISOLONE SODIUM SUCCINATE, DIPHENHYDRAMINE HYDROCHLORIDE, PREDNISONE, RITUXIMAB, BEKEMV 300 mg concentrate for solution for infusion, DIPHENHYDRAMINE HYDROCHLORIDE, METHYLPREDNISOLONE SODIUM SUCCINATE, PARACETAMOL, ECULIZUMAB, PREDNISONE, SIROLIMUS, RITUXIMAB, BEKEMV 300 mg concentrate for solution for infusion, SIROLIMUS, PREDNISONE","productRoleCode":"4","productRoleName":"Auxiliary","products":[{"id":610885,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10537MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"SIROLIMUS","pharmForm":"ORAL SOLUTION","activeSubstanceName":"SIROLIMUS","euSubstNumber":"SUB10537MIG","productSubstances":[{"substancePk":"144388","actSubstOrigin":"Chemical","actSubstName":"SIROLIMUS","substanceEvCode":"SUB10537MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/17/1910","doseUom":"mg milligram(s)","maxDailyDoseAmount":"2","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"2","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","scientificProductEvCode":"SUB10537MIG","devices":[],"characteristics":["4"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"SIROLIMUS","jsonActiveSubstanceNames":"sirolimus"},{"id":610886,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11582300","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD10444544","marketingAuthNumber":"EU/1/23/1735/001","prodAuthStatus":2,"prodName":"Epysqli 300 mg concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"ECULIZUMAB","euSubstNumber":"SUB25187","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/006036","nameOrg":"SAMSUNG BIOEPIS NL B.V.","productSubstances":[{"productPk":"11582300","substancePk":"376568","nameOrg":"SAMSUNG BIOEPIS NL B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"ECULIZUMAB","substanceEvCode":"SUB25187","synonyms":["ABP-959","H5G1.1"]}],"atcCode":"L04AA25","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"1200","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"1200","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Humanised monoclonal antibody","evCode":"PRD10444544","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS ADMINISTRATION"],"allSubstancesChemicals":false,"productName":"Epysqli 300 mg concentrate for solution for infusion","jsonActiveSubstanceNames":"eculizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":610887,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB09611MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PARACETAMOL","pharmForm":"TABLET","activeSubstanceName":"PARACETAMOL","euSubstNumber":"SUB09611MIG","productSubstances":[{"substancePk":"261177","actSubstOrigin":"Chemical","actSubstName":"PARACETAMOL","substanceEvCode":"SUB09611MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"g gram(s)","maxDailyDoseAmount":"1","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"1","productChangedRelationMA":false,"maxTreatmentPeriod":2,"timeUnitCode":"2","otherMedicinalProduct":"Substance of chemical origin","scientificProductEvCode":"SUB09611MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"PARACETAMOL","jsonActiveSubstanceNames":"paracetamol"},{"id":610888,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10537MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"SIROLIMUS","pharmForm":"COATED TABLET","activeSubstanceName":"SIROLIMUS","euSubstNumber":"SUB10537MIG","productSubstances":[{"substancePk":"233258","actSubstOrigin":"Chemical","actSubstName":"SIROLIMUS","substanceEvCode":"SUB10537MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/17/1910","doseUom":"mg milligram(s)","maxDailyDoseAmount":"2","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"2","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","scientificProductEvCode":"SUB10537MIG","devices":[],"characteristics":["4"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"SIROLIMUS","jsonActiveSubstanceNames":"sirolimus"},{"id":610889,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10020MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PREDNISONE","pharmForm":"TABLET","activeSubstanceName":"PREDNISONE","euSubstNumber":"SUB10020MIG","productSubstances":[{"substancePk":"172490","actSubstOrigin":"Chemical","actSubstName":"PREDNISONE","substanceEvCode":"SUB10020MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"60","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"60","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Corticosteroid","scientificProductEvCode":"SUB10020MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"PREDNISONE","jsonActiveSubstanceNames":"prednisone"},{"id":610890,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10020MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PREDNISONE","pharmForm":"TABLET","activeSubstanceName":"PREDNISONE","euSubstNumber":"SUB10020MIG","productSubstances":[{"substancePk":"43852","actSubstOrigin":"Chemical","actSubstName":"PREDNISONE","substanceEvCode":"SUB10020MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"60","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"60","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Corticosteroid","scientificProductEvCode":"SUB10020MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"PREDNISONE","jsonActiveSubstanceNames":"prednisone"},{"id":610891,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11336214","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD10458812","marketingAuthNumber":"EU/1/23/1727/001","prodAuthStatus":2,"prodName":"BEKEMV 300 mg concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"ECULIZUMAB","euSubstNumber":"SUB25187","authorisationCountryCode":"NO","mrpNumber":"EMEA/H/C/005652","nameOrg":"AMGEN TECHNOLOGY (IRELAND) UC","productSubstances":[{"productPk":"11336214","substancePk":"376568","nameOrg":"AMGEN TECHNOLOGY (IRELAND) UC","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"ECULIZUMAB","substanceEvCode":"SUB25187","synonyms":["ABP-959","H5G1.1"]}],"atcCode":"L04AA25","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"1200","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"1200","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Humanised monoclonal antibody","evCode":"PRD10458812","devices":[],"characteristics":["11"],"routes":["INTRAVENIOUS INFUSION"],"allSubstancesChemicals":false,"productName":"BEKEMV 300 mg concentrate for solution for infusion","jsonActiveSubstanceNames":"eculizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":610892,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB14562MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"METHYLPREDNISOLONE SODIUM SUCCINATE","pharmForm":"POWDER FOR SOLUTION FOR INFUSION","activeSubstanceName":"METHYLPREDNISOLONE SODIUM SUCCINATE","euSubstNumber":"SUB14562MIG","productSubstances":[{"substancePk":"27047","actSubstOrigin":"-","actSubstName":"METHYLPREDNISOLONE SODIUM SUCCINATE","substanceEvCode":"SUB14562MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg/kg milligram(s)/kilogram","maxDailyDoseAmount":"0.8","doseUomTotal":"mg/kg milligram(s)/kilogram","maxTotalDoseAmount":"0.8","productChangedRelationMA":false,"maxTreatmentPeriod":4,"timeUnitCode":"1","otherMedicinalProduct":"Corticosteroid","scientificProductEvCode":"SUB14562MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"METHYLPREDNISOLONE SODIUM SUCCINATE","jsonActiveSubstanceNames":"methylprednisolone sodium succinate"},{"id":610893,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB01769MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"DIPHENHYDRAMINE HYDROCHLORIDE","pharmForm":"TABLET","activeSubstanceName":"DIPHENHYDRAMINE HYDROCHLORIDE","euSubstNumber":"SUB01769MIG","productSubstances":[{"substancePk":"27029","actSubstOrigin":"-","actSubstName":"DIPHENHYDRAMINE HYDROCHLORIDE","substanceEvCode":"SUB01769MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"50","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"50","productChangedRelationMA":false,"maxTreatmentPeriod":2,"timeUnitCode":"2","otherMedicinalProduct":"Substance of chemical origin","scientificProductEvCode":"SUB01769MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"DIPHENHYDRAMINE HYDROCHLORIDE","jsonActiveSubstanceNames":"diphenhydramine hydrochloride"},{"id":610894,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10020MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PREDNISONE","pharmForm":"TABLET","activeSubstanceName":"PREDNISONE","euSubstNumber":"SUB10020MIG","productSubstances":[{"substancePk":"266824","actSubstOrigin":"Chemical","actSubstName":"PREDNISONE","substanceEvCode":"SUB10020MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"60","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"60","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Corticosteroid","scientificProductEvCode":"SUB10020MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"PREDNISONE","jsonActiveSubstanceNames":"prednisone"},{"id":610895,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB12570MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"RITUXIMAB","pharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","activeSubstanceName":"RITUXIMAB","euSubstNumber":"SUB12570MIG","productSubstances":[{"substancePk":"24724","actSubstOrigin":"-","actSubstName":"RITUXIMAB","substanceEvCode":"SUB12570MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/17/1869","doseUom":"mg/m2 milligram(s)/square meter","maxDailyDoseAmount":"750","doseUomTotal":"mg/m2 milligram(s)/square meter","maxTotalDoseAmount":"750","productChangedRelationMA":false,"maxTreatmentPeriod":2,"timeUnitCode":"2","scientificProductEvCode":"SUB12570MIG","devices":[],"characteristics":["4"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":false,"productName":"RITUXIMAB","jsonActiveSubstanceNames":"rituximab"},{"id":610896,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11336212","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD10421748","marketingAuthNumber":"EU/1/23/1727/001","prodAuthStatus":2,"prodName":"BEKEMV 300 mg concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"ECULIZUMAB","euSubstNumber":"SUB25187","authorisationCountryCode":"IS","mrpNumber":"EMEA/H/C/005652","nameOrg":"AMGEN TECHNOLOGY (IRELAND) UC","productSubstances":[{"productPk":"11336212","substancePk":"376568","nameOrg":"AMGEN TECHNOLOGY (IRELAND) UC","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"ECULIZUMAB","substanceEvCode":"SUB25187","synonyms":["ABP-959","H5G1.1"]}],"atcCode":"L04AA25","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"1200","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"1200","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Humanised monoclonal antibody","evCode":"PRD10421748","devices":[],"characteristics":["11"],"routes":["INTRAVENIOUS INFUSION"],"allSubstancesChemicals":false,"productName":"BEKEMV 300 mg concentrate for solution for infusion","jsonActiveSubstanceNames":"eculizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":610897,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB01769MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"DIPHENHYDRAMINE HYDROCHLORIDE","pharmForm":"TABLET","activeSubstanceName":"DIPHENHYDRAMINE HYDROCHLORIDE","euSubstNumber":"SUB01769MIG","productSubstances":[{"substancePk":"172561","actSubstOrigin":"Chemical","actSubstName":"DIPHENHYDRAMINE HYDROCHLORIDE","substanceEvCode":"SUB01769MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"50","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"50","productChangedRelationMA":false,"maxTreatmentPeriod":2,"timeUnitCode":"2","otherMedicinalProduct":"Substance of chemical origin","scientificProductEvCode":"SUB01769MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"DIPHENHYDRAMINE HYDROCHLORIDE","jsonActiveSubstanceNames":"diphenhydramine hydrochloride"},{"id":610898,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB14562MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"METHYLPREDNISOLONE SODIUM SUCCINATE","pharmForm":"POWDER FOR SOLUTION FOR INFUSION","activeSubstanceName":"METHYLPREDNISOLONE SODIUM SUCCINATE","euSubstNumber":"SUB14562MIG","productSubstances":[{"substancePk":"27047","actSubstOrigin":"-","actSubstName":"METHYLPREDNISOLONE SODIUM SUCCINATE","substanceEvCode":"SUB14562MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg/kg milligram(s)/kilogram","maxDailyDoseAmount":"0.8","doseUomTotal":"mg/kg milligram(s)/kilogram","maxTotalDoseAmount":"0.8","productChangedRelationMA":false,"maxTreatmentPeriod":4,"timeUnitCode":"2","otherMedicinalProduct":"Corticosteroid","scientificProductEvCode":"SUB14562MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"METHYLPREDNISOLONE SODIUM SUCCINATE","jsonActiveSubstanceNames":"methylprednisolone sodium succinate"},{"id":610899,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB09611MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PARACETAMOL","pharmForm":"TABLET","activeSubstanceName":"PARACETAMOL","euSubstNumber":"SUB09611MIG","productSubstances":[{"substancePk":"119150","actSubstOrigin":"Chemical","actSubstName":"PARACETAMOL","substanceEvCode":"SUB09611MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"g gram(s)","maxDailyDoseAmount":"1","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"1","productChangedRelationMA":false,"maxTreatmentPeriod":2,"timeUnitCode":"2","otherMedicinalProduct":"Substance of chemical origin","scientificProductEvCode":"SUB09611MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"PARACETAMOL","jsonActiveSubstanceNames":"paracetamol"},{"id":610900,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB25187","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"ECULIZUMAB","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"ECULIZUMAB","euSubstNumber":"SUB25187","productSubstances":[{"substancePk":"273378","actSubstOrigin":"Protein - Other","actSubstName":"ECULIZUMAB","substanceEvCode":"SUB25187"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/14/1304","doseUom":"mg milligram(s)","maxDailyDoseAmount":"1200","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"1200","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Humanised monoclonal antibody","scientificProductEvCode":"SUB25187","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":false,"productName":"ECULIZUMAB","jsonActiveSubstanceNames":"eculizumab"},{"id":610901,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10020MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PREDNISONE","pharmForm":"TABLET","activeSubstanceName":"PREDNISONE","euSubstNumber":"SUB10020MIG","productSubstances":[{"substancePk":"173026","actSubstOrigin":"Chemical","actSubstName":"PREDNISONE","substanceEvCode":"SUB10020MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"60","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"60","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Corticosteroid","scientificProductEvCode":"SUB10020MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"PREDNISONE","jsonActiveSubstanceNames":"prednisone"},{"id":610902,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10537MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"SIROLIMUS","pharmForm":"COATED TABLET","activeSubstanceName":"SIROLIMUS","euSubstNumber":"SUB10537MIG","productSubstances":[{"substancePk":"233258","actSubstOrigin":"Chemical","actSubstName":"SIROLIMUS","substanceEvCode":"SUB10537MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/17/1910","doseUom":"mg milligram(s)","maxDailyDoseAmount":"2","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"2","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","scientificProductEvCode":"SUB10537MIG","devices":[],"characteristics":["4"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"SIROLIMUS","jsonActiveSubstanceNames":"sirolimus"},{"id":610903,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB12570MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"RITUXIMAB","pharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","activeSubstanceName":"RITUXIMAB","euSubstNumber":"SUB12570MIG","productSubstances":[{"substancePk":"24724","actSubstOrigin":"-","actSubstName":"RITUXIMAB","substanceEvCode":"SUB12570MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/17/1869","doseUom":"mg/m2 milligram(s)/square meter","maxDailyDoseAmount":"750","doseUomTotal":"mg/m2 milligram(s)/square meter","maxTotalDoseAmount":"750","productChangedRelationMA":false,"maxTreatmentPeriod":2,"timeUnitCode":"2","scientificProductEvCode":"SUB12570MIG","devices":[],"characteristics":["4"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":false,"productName":"RITUXIMAB","jsonActiveSubstanceNames":"rituximab"},{"id":610904,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11336213","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD10347676","marketingAuthNumber":"EU/1/23/1727/001","prodAuthStatus":2,"prodName":"BEKEMV 300 mg concentrate for solution for infusion","pharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","activeSubstanceName":"ECULIZUMAB","euSubstNumber":"SUB25187","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/005652","nameOrg":"AMGEN TECHNOLOGY (IRELAND) UC","productSubstances":[{"productPk":"11336213","substancePk":"376568","nameOrg":"AMGEN TECHNOLOGY (IRELAND) UC","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"ECULIZUMAB","substanceEvCode":"SUB25187","synonyms":["ABP-959","H5G1.1"]}],"atcCode":"L04AA25","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"1200","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"1200","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Humanised monoclonal antibody","evCode":"PRD10347676","devices":[],"characteristics":["11"],"routes":["INTRAVENIOUS INFUSION"],"allSubstancesChemicals":false,"productName":"BEKEMV 300 mg concentrate for solution for infusion","jsonActiveSubstanceNames":"eculizumab","pharmaceuticalFormDisplay":"CONCENTRATE FOR SOLUTION FOR INFUSION"},{"id":610905,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10537MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"SIROLIMUS","pharmForm":"COATED TABLET","activeSubstanceName":"SIROLIMUS","euSubstNumber":"SUB10537MIG","productSubstances":[{"substancePk":"144388","actSubstOrigin":"Chemical","actSubstName":"SIROLIMUS","substanceEvCode":"SUB10537MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":true,"orphanDrugDesigNumber":"EU/3/17/1910","doseUom":"mg milligram(s)","maxDailyDoseAmount":"2","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"2","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","scientificProductEvCode":"SUB10537MIG","devices":[],"characteristics":["4"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"SIROLIMUS","jsonActiveSubstanceNames":"sirolimus"},{"id":610906,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB10020MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PREDNISONE","pharmForm":"TABLET","activeSubstanceName":"PREDNISONE","euSubstNumber":"SUB10020MIG","productSubstances":[{"substancePk":"287401","actSubstOrigin":"Chemical","actSubstName":"PREDNISONE","substanceEvCode":"SUB10020MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"4","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"60","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"60","productChangedRelationMA":false,"maxTreatmentPeriod":3,"timeUnitCode":"3","otherMedicinalProduct":"Corticosteroid","scientificProductEvCode":"SUB10020MIG","devices":[],"characteristics":["11"],"routes":["ORAL USE"],"allSubstancesChemicals":false,"productName":"PREDNISONE","jsonActiveSubstanceNames":"prednisone"}]},{"id":452291,"comments":"AAV9.LAMP2B","miaNumber":"108630F","productRoleCode":"1","productRoleName":"Test","products":[{"id":610907,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10873488","productPharmForm":"SOLUTION FOR INFUSION","euMpNumber":"PRD10873488","prodAuthStatus":1,"prodName":"AAV9.LAMP2B","pharmForm":"SOLUTION FOR INFUSION","sponsorProductCode":"RP-A501","activeSubstanceName":"ADENO-ASSOCIATED VIRUS SEROTYPE 9 VECTOR CONTAINING THE HUMAN LAMP2 ISOFORM B TRANSGENE","euSubstNumber":"SUB316904","productOtherName":"Recombinant Adeno-associated virus serotype 9\nvector containing the human-lysosome-associated\nmembrane glycoprotein 2 isoform B transgene","nameOrg":"ROCKET PHARMACEUTICALS, INC","productSubstances":[{"productPk":"10873488","substancePk":"324593","nameOrg":"ROCKET PHARMACEUTICALS, INC","substanceOrigin":"Structurally Diverse Substance - Other","actSubstOrigin":"Structurally Diverse Substance - Other","actSubstName":"ADENO-ASSOCIATED VIRUS SEROTYPE 9 VECTOR CONTAINING THE HUMAN LAMP2 ISOFORM B TRANSGENE","substanceEvCode":"SUB316904","synonyms":["RP-A501","Recombinant adeno-associated virus serotype 9 vector containing the human-lysosome-associated membrane glycoprotein 2 isoform B transgene"]}],"atcCode":"A16AX","atcName":"VARIOUS ALIMENTARY TRACT AND METABOLISM PRODUCTS","atcTermLevel":"4","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":true,"orphanDrugDesigNumber":"EMA/OD/0000141142","doseUom":"Other","maxDailyDoseAmount":"67000000000000","doseUomTotal":"Other","maxTotalDoseAmount":"67000000000000","maxTreatmentPeriod":1,"timeUnitCode":"1","evCode":"PRD10873488","sponsorProductCodeEdit":"RP-A501","miaNumber":"108630F","therapies":[{"id":7904,"catReferenceNumber":"EMA/CAT/219514/2023","advancedTherapyType":"3","geneOfInterest":"LAMP2B","description":"Adeno-Associated Virus Serotype 9 (rAAV9) Vector","isGmo":false,"isInVivo":true,"geneTransferProductType":"3"}],"devices":[],"characteristics":["7","8"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":false,"productName":"AAV9.LAMP2B","jsonActiveSubstanceNames":"adeno-associated virus serotype 9 vector containing the human lamp2 isoform b transgene","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":327785,"mscId":31896,"mscInfo":{"id":31896,"clinicalTrialId":6846,"countryOrganisationId":2018,"reportingStatusCode":"Authorised","fromDate":"2024-08-01","toDate":"2024-08-01","isProposedRms":false,"countryName":"Italy","organisationInfo":{},"firstDecisionDate":"2024-08-28","trialStatus":"Authorised","trialPeriod":[{"id":40706,"trialStartDate":"2024-10-29","fromDate":"2024-10-30"},{"id":40707,"trialStartDate":"2024-10-29","fromDate":"2024-10-30"},{"id":75810,"trialStartDate":"2026-02-26","fromDate":"2026-02-26"},{"id":75811,"trialStartDate":"2026-02-26","fromDate":"2026-02-26"}],"trialRecruitmentPeriod":[{"id":69548,"recruitmentStartDate":"2025-01-20","fromDate":"2025-03-06"},{"id":69549,"recruitmentStartDate":"2025-01-20","fromDate":"2025-03-06"},{"id":78260,"recruitmentStartDate":"2025-01-20","recruitmentEndDate":"2025-05-25","fromDate":"2025-06-02"},{"id":78261,"recruitmentStartDate":"2025-01-20","recruitmentEndDate":"2025-05-25","fromDate":"2025-06-02"},{"id":102493,"recruitmentStartDate":"2026-02-26","fromDate":"2026-03-03"},{"id":102494,"recruitmentStartDate":"2026-02-26","fromDate":"2026-03-03"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":54961,"trialStartDate":"2024-10-29","fromDate":"2024-10-30"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-01-20"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":38026,"mscId":31896,"trialStatus":"Under evaluation","trialStatusDate":"2024-06-10T21:28:32.585"},{"id":50090,"mscId":31896,"trialStatus":"Authorised","trialStatusDate":"2024-08-28T19:54:13.802"},{"id":84158,"mscId":31896,"trialStatus":"Halted","trialStatusDate":"2025-06-02T13:34:05.987"},{"id":293631,"mscId":31896,"trialStatus":"Authorised","trialStatusDate":"2026-02-26T12:50:00.476"}],"applicationTypeMsc":"3","mscName":"Italy","trialRestartDate":"2026-02-26","recruitmentRestartDate":"2026-02-26","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-20","decision":"authorized","decisionDate":"2024-08-28"},"decisionDate":"2024-08-28","recruitmentSubjectCount":2,"trialSites":[{"id":2300454,"organisationAddressInfo":{"id":461974,"organisation":{"id":494290,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Azienda Ospedaliera Universitaria Meyer IRCCS","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100012218","organisationLocationStatus":"Active"},"address":{"addressId":495252,"oneLine":"Viale Gaetano Pieraccini 24","addressLine1":"Viale Gaetano Pieraccini 24","addressLine2":"","addressLine3":"","addressLine4":"","city":"Florence","postcode":"50139","country":2018,"countryName":"Italy"},"phone":"3313334844","email":"Iacopo.olivotto@unifi.it","isBusinessKeyValidated":true,"businessKey":"ORG-100012218"},"personInfo":{"id":2550328,"firstName":"Iacopo","lastName":"Olivotto","telephone":"3313334844","email":"Iacopo.olivotto@unifi.it","title":"2"},"departmentName":"Cardiology"}],"applicationStatusCode":"Authorised"},{"id":327846,"mscId":60312,"mscInfo":{"id":60312,"clinicalTrialId":6846,"countryOrganisationId":2027,"reportingStatusCode":"Authorised","fromDate":"2026-07-31","toDate":"2026-07-31","isProposedRms":false,"countryName":"Spain","organisationInfo":{},"firstDecisionDate":"2026-08-31","trialStatus":"Authorised","trialPeriod":[],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":412620,"mscId":60312,"trialStatus":"Under evaluation","trialStatusDate":"2026-06-02T16:56:27.634"},{"id":472970,"mscId":60312,"trialStatus":"Authorised","trialStatusDate":"2026-08-31T10:46:26.327"}],"applicationTypeMsc":"3","mscName":"Spain","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-24","decision":"authorized","decisionDate":"2026-08-31"},"decisionDate":"2026-08-31","recruitmentSubjectCount":2,"trialSites":[{"id":2301601,"organisationAddressInfo":{"id":972483,"organisation":{"id":1015944,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Sant Joan De Deu Barcelona","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100023083","organisationLocationStatus":"Active"},"address":{"addressId":1094577,"oneLine":"Passeig De Sant Joan De Deu 2","addressLine1":"Passeig De Sant Joan De Deu 2","addressLine2":"","addressLine3":"","addressLine4":"","city":"Esplugues De Llobregat","postcode":"08950","country":2027,"countryName":"Spain"},"phone":"932532100","email":"frecerca.startup@sjd.es","isBusinessKeyValidated":true,"businessKey":"ORG-100023083"},"personInfo":{"id":2551511,"firstName":"Georgia","lastName":"Sarquella","telephone":"932532100","email":"frecerca.startup@sjd.es"},"departmentName":"Cardiology"}],"applicationStatusCode":"Authorised"},{"id":343940,"mscId":15772,"mscInfo":{"id":15772,"clinicalTrialId":6846,"countryOrganisationId":2013,"reportingStatusCode":"Authorised","fromDate":"2023-12-07","toDate":"2023-12-07","isProposedRms":true,"countryName":"Germany","organisationInfo":{},"firstDecisionDate":"2024-01-19","trialStatus":"Authorised","trialPeriod":[{"id":23286,"trialStartDate":"2024-06-18","fromDate":"2024-06-21"},{"id":23287,"trialStartDate":"2024-06-18","fromDate":"2024-06-21"},{"id":75812,"trialStartDate":"2026-02-26","fromDate":"2026-02-26"},{"id":75813,"trialStartDate":"2026-02-26","fromDate":"2026-02-26"}],"trialRecruitmentPeriod":[{"id":33011,"recruitmentStartDate":"2024-07-08","fromDate":"2024-07-15"},{"id":69522,"recruitmentStartDate":"2024-07-08","fromDate":"2025-03-06"},{"id":69523,"recruitmentStartDate":"2024-07-08","fromDate":"2025-03-06"},{"id":78258,"recruitmentStartDate":"2024-07-08","recruitmentEndDate":"2025-05-25","fromDate":"2025-06-02"},{"id":78259,"recruitmentStartDate":"2024-07-08","recruitmentEndDate":"2025-05-25","fromDate":"2025-06-02"},{"id":102491,"recruitmentStartDate":"2026-02-26","fromDate":"2026-03-03"},{"id":102492,"recruitmentStartDate":"2026-02-26","fromDate":"2026-03-03"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":30770,"trialStartDate":"2024-06-18","fromDate":"2024-06-21"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2024-07-08"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":14577,"mscId":15772,"trialStatus":"Under evaluation","trialStatusDate":"2023-10-20T17:47:42.12"},{"id":21149,"mscId":15772,"trialStatus":"Authorised","trialStatusDate":"2024-01-19T14:48:57.869"},{"id":84157,"mscId":15772,"trialStatus":"Halted","trialStatusDate":"2025-06-02T13:34:05.874"},{"id":293632,"mscId":15772,"trialStatus":"Authorised","trialStatusDate":"2026-02-26T12:50:00.53"}],"applicationTypeMsc":"1","mscName":"Germany","trialRestartDate":"2026-02-26","recruitmentRestartDate":"2026-02-26","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-09","decision":"authorized","decisionDate":"2024-01-19"},"decisionDate":"2024-01-19","recruitmentSubjectCount":6,"trialSites":[{"id":2417332,"organisationAddressInfo":{"id":230534,"organisation":{"id":234286,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Deutsches Herzzentrum Muenchen Des Freistaates Bayern Klinik An Der Technischen Universitaet Muenchen","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009127","organisationLocationStatus":"Active"},"address":{"addressId":245597,"oneLine":"Lazarettstrasse 36, Neuhausen-Nymphenburg","addressLine1":"Lazarettstrasse 36","addressLine2":"Neuhausen-Nymphenburg","addressLine3":"","addressLine4":"","city":"Munich","postcode":"80636","country":2013,"countryName":"Germany"},"phone":"+498912180","email":"dhm@dhm.mhn.de","isBusinessKeyValidated":true,"businessKey":"ORG-100009127"},"personInfo":{"id":2679177,"firstName":"Cordula","lastName":"Wolf","telephone":"+498912180","email":"dhm@dhm.mhn.de","title":"1"},"departmentName":"Department of Congenital Heart Defects and Pediatric Cardiology"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":9282,"type":"INITIAL","status":"Authorised","ctNumber":"2023-506480-34-00","trialStatus":"Authorised","submissionDate":"2023-10-20","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-01-18"},"partIIInfo":[{"id":56436,"mscId":15772,"mscInfo":{"id":15772,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-01-04","decision":"authorized","decisionDate":"2024-01-19","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-01-19"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-01-19","ctMSCsByApplication":[{"id":15772,"mscName":"Germany","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":11461,"applicationId":9282,"mscId":15772,"mscName":"Germany","decisionDate":"2024-01-19T14:48:58.345","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":56436,"part1Id":25153,"applicationType":"INITIAL","isRMS":true}]},{"id":23375,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506480-34-00","trialStatus":"Authorised","submissionDate":"2024-04-15","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-05-15"},"partIIInfo":[{"id":85565,"mscId":15772,"mscInfo":{"id":15772,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-05-15","decision":"authorized","decisionDate":"2024-01-19","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-01-19"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-05-17","ctMSCsByApplication":[{"id":15772,"mscName":"Germany","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":21969,"applicationId":23375,"mscId":15772,"mscName":"Germany","decisionDate":"2024-05-17T15:41:32.524","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":85565,"part1Id":34745,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]},{"id":27019,"type":"SUBSEQUENT ADDITION OF MSC","status":"Authorised","ctNumber":"2023-506480-34-00","trialStatus":"Authorised","submissionDate":"2024-06-10","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-05-15"},"partIIInfo":[{"id":124910,"mscId":31896,"mscInfo":{"id":31896,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-08-19","decision":"authorized","decisionDate":"2024-08-28","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2024-08-28"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-08-28","ctMSCsByApplication":[{"id":31896,"mscName":"Italy","reportingStatusCode":"Authorised"}],"businessKey":"AM-1","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":35427,"applicationId":27019,"mscId":31896,"mscName":"Italy","decisionDate":"2024-08-28T19:54:14.111","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":124910,"part1Id":40597,"applicationType":"SUBSEQUENT ADDITION OF MSC","isRMS":false}]},{"id":40440,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506480-34-00","trialStatus":"Authorised","submissionDate":"2024-11-21","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-11"},"partIIInfo":[{"id":163178,"mscId":15772,"mscInfo":{"id":15772,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-10","decision":"authorized","decisionDate":"2024-01-19","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-01-19"},"applicationStatusCode":"Authorised"},{"id":155258,"mscId":31896,"mscInfo":{"id":31896,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-01-09","decision":"authorized","decisionDate":"2024-08-28","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2024-08-28"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-02-11","ctMSCsByApplication":[{"id":15772,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":31896,"mscName":"Italy","reportingStatusCode":"Authorised"}],"businessKey":"SM-2","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":57415,"applicationId":40440,"mscId":15772,"mscName":"Germany","decisionDate":"2025-02-11T14:50:10.239","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":163178,"part1Id":71660,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true},{"id":57851,"applicationId":40440,"mscId":31896,"mscName":"Italy","decisionDate":"2025-02-13T15:06:15.194","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":155258,"part1Id":71660,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}]},{"id":68966,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506480-34-00","trialStatus":"Authorised","submissionDate":"2025-11-07","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-02-23"},"partIIInfo":[{"id":254108,"mscId":15772,"mscInfo":{"id":15772,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"no_conclusion","assessmentOutcomeDate":"2026-01-26","decision":"authorized","decisionDate":"2024-01-19","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-01-19"},"applicationStatusCode":"Authorised"},{"id":254107,"mscId":31896,"mscInfo":{"id":31896,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-01-23","decision":"authorized","decisionDate":"2024-08-28","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2024-08-28"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-02-25","ctMSCsByApplication":[{"id":15772,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":31896,"mscName":"Italy","reportingStatusCode":"Authorised"}],"businessKey":"SM-4","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":111650,"applicationId":68966,"mscId":31896,"mscName":"Italy","decisionDate":"2026-02-25T18:20:28.571","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":254107,"part1Id":106176,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":111563,"applicationId":68966,"mscId":15772,"mscName":"Germany","decisionDate":"2026-02-25T12:58:53.187","decision":"authorized","assessmentOutcome":"no_conclusion","eventType":"decision","part2Id":254108,"part1Id":106176,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]},{"id":83915,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506480-34-00","trialStatus":"Authorised","submissionDate":"2026-05-15","partI":{"assessmentOutcome":"acceptable"},"partIIInfo":[{"id":303364,"mscId":15772,"mscInfo":{"id":15772,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-06-03","decision":"authorized","decisionDate":"2024-01-19","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-01-19"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-06-09","ctMSCsByApplication":[{"id":15772,"mscName":"Germany","reportingStatusCode":"Authorised"}],"businessKey":"SM-5","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":127648,"applicationId":83915,"mscId":15772,"mscName":"Germany","decisionDate":"2026-06-09T09:28:35.061","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":303364,"part1Id":128446,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]},{"id":83917,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506480-34-00","trialStatus":"Authorised","submissionDate":"2026-05-21","partI":{"assessmentOutcome":"acceptable"},"partIIInfo":[{"id":327785,"mscId":31896,"mscInfo":{"id":31896,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-20","decision":"authorized","decisionDate":"2024-08-28","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2024-08-28"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-08-24","ctMSCsByApplication":[{"id":31896,"mscName":"Italy","reportingStatusCode":"Authorised"}],"businessKey":"SM-6","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":138940,"applicationId":83917,"mscId":31896,"mscName":"Italy","decisionDate":"2026-08-24T13:49:45.893","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":327785,"part1Id":128448,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}]},{"id":83920,"type":"SUBSEQUENT ADDITION OF MSC","status":"Authorised","ctNumber":"2023-506480-34-00","trialStatus":"Authorised","submissionDate":"2026-06-02","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-02-23"},"partIIInfo":[{"id":327846,"mscId":60312,"mscInfo":{"id":60312,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-24","decision":"authorized","decisionDate":"2026-08-31","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2026-08-31"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-08-31","ctMSCsByApplication":[{"id":60312,"mscName":"Spain","reportingStatusCode":"Authorised"}],"businessKey":"AM-2","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":139805,"applicationId":83920,"mscId":60312,"mscName":"Spain","decisionDate":"2026-08-31T10:46:26.658","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":327846,"part1Id":128453,"applicationType":"SUBSEQUENT ADDITION OF MSC","isRMS":false}]},{"id":95788,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-506480-34-00","trialStatus":"Authorised","submissionDate":"2026-10-01","partI":{"assessmentOutcome":"acceptable"},"partIIInfo":[{"id":343940,"mscId":15772,"mscInfo":{"id":15772,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-09","decision":"authorized","decisionDate":"2024-01-19","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2024-01-19"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-10-13","ctMSCsByApplication":[{"id":15772,"mscName":"Germany","reportingStatusCode":"Authorised"}],"businessKey":"SM-7","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":146196,"applicationId":95788,"mscId":15772,"mscName":"Germany","decisionDate":"2026-10-13T10:49:14.849","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":343940,"part1Id":146130,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Germany","mscId":15772,"firstDecisionDate":"2024-01-19T14:48:58.345","lastDecisionDate":"2026-10-13T10:49:14.849","mscPublicStatusCode":4},{"mscName":"Italy","mscId":31896,"firstDecisionDate":"2024-08-28T19:54:14.111","lastDecisionDate":"2026-08-24T13:49:45.893","mscPublicStatusCode":4},{"mscName":"Spain","mscId":60312,"firstDecisionDate":"2026-08-31T10:46:26.658","lastDecisionDate":"2026-08-31T10:46:26.658","mscPublicStatusCode":2}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[{"mscId":31896,"businessKey":"TH-84979","haltDate":"2025-05-25","reasonList":[{"code":"1","name":"Sponsor decision","isSmRequiredForRestart":true,"isCommentRequired":false},{"code":"4","name":"Safety related (clinical or pre-clinical results)","isSmRequiredForRestart":false,"isCommentRequired":false}],"isTreatmentStopped":true,"sponsorJustificationComment":"Per protocol, study enrollment was suspended and planned treatment of any new subjects with RP-A501 was halted on 07-May-2025. This was based on previously reported SAEs events (CIOMS submission dates of 15-May-2025 and 20-May-2025). Subsequently, the Sponsor received FDA notification of clinical hold. One subject developed bacteremia and sepsis which subsequently resulted in death on 25-May-2025.","bnftRskBalanceChngJstfctn":"The subject developed bacteremia and sepsis which subsequently resulted in death on 25-May-2025.\nThe CIOMS is due for submission on 03-Jun-2025.","isBenefitRiskBalanceChange":true,"submitDate":"2025-06-02T13:34:05","subjectFuMeasuresComment":"An investigation is currently ongoing. Per protocol, study enrollment was suspended and planned treatment of any new subjects with RP-A501 was halted on 07-May-2025.","isPublished":false,"mscList":[{"mscId":31896,"mscCountryName":"Italy","mscCountryCode":"IT"}]},{"mscId":15772,"businessKey":"TH-84977","haltDate":"2025-05-25","reasonList":[{"code":"1","name":"Sponsor decision","isSmRequiredForRestart":true,"isCommentRequired":false},{"code":"4","name":"Safety related (clinical or pre-clinical results)","isSmRequiredForRestart":false,"isCommentRequired":false}],"isTreatmentStopped":true,"sponsorJustificationComment":"Per protocol, study enrollment was suspended and planned treatment of any new subjects with RP-A501 was halted on 07-May-2025. This was based on previously reported SAEs events (CIOMS submission dates of 15-May-2025 and 20-May-2025). Subsequently, the Sponsor received FDA notification of clinical hold. One subject developed bacteremia and sepsis which subsequently resulted in death on 25-May-2025.","bnftRskBalanceChngJstfctn":"The subject developed bacteremia and sepsis which subsequently resulted in death on 25-May-2025.\nThe CIOMS is due for submission on 03-Jun-2025.","isBenefitRiskBalanceChange":true,"submitDate":"2025-06-02T13:34:05","subjectFuMeasuresComment":"An investigation is currently ongoing. Per protocol, study enrollment was suspended and planned treatment of any new subjects with RP-A501 was halted on 07-May-2025.","isPublished":false,"mscList":[{"mscId":15772,"mscCountryName":"Germany","mscCountryCode":"DE"}]}],"trialEvents":[{"mscId":15772,"mscName":"Germany","events":[{"notificationType":"START_OF_TRIAL","date":"2024-06-18"},{"notificationType":"RESTART_OF_TRIAL","date":"2026-02-26"},{"notificationType":"RESTART_OF_RECRUITMENT","date":"2026-02-26"},{"notificationType":"START_OF_RECRUITMENT","date":"2024-07-08"},{"notificationType":"TEMPORARY_HALT","date":"2025-05-25"}]},{"mscId":31896,"mscName":"Italy","events":[{"notificationType":"START_OF_TRIAL","date":"2024-10-29"},{"notificationType":"RESTART_OF_TRIAL","date":"2026-02-26"},{"notificationType":"RESTART_OF_RECRUITMENT","date":"2026-02-26"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-01-20"},{"notificationType":"TEMPORARY_HALT","date":"2025-05-25"}]},{"mscId":60312,"mscName":"Spain","events":[]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"D1_RP-A501-0123_Protocol 2023-506480-34-00_Redacted","uuid":"aa7e4385-c0b0-45b2-9d46-3ed2e0b8613a","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"5.0","systemVersion":"6"},{"title":"D4_RP-A501-0123_Patient facing documents KCCQ12_DE_Redacted","uuid":"412abc61-1d60-47d4-b823-62be4b61f3b2","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"na","systemVersion":"1"},{"title":"D4_RP-A501-0123_Patient facing documents KCCQ12 SO_DE","uuid":"ed100883-8f61-4ce8-935d-8a200417a6a7","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"1.0","systemVersion":"1"},{"title":"D1_RP-A501-0123_Laboratory Manual 2023-506480-34-00_Redacted","uuid":"ae8a4d04-2606-49ff-93fd-4b62e035cd58","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"1","systemVersion":"2"},{"title":"D1_RP-A501-0123_Clinical Risk Management Plan 2023-506480-34-00_Redacted","uuid":"f416be8c-171b-473b-9175-ff68a0d018cb","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"1","systemVersion":"2"},{"title":"D1_RP-A501-0123_Pharmacy Manual 2023-506480-34-00_Redacted","uuid":"ff0cd210-11ab-4c24-afc0-20c05430b45f","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"1","systemVersion":"2"},{"title":"D4_RP-A501-0123_PFD_Sponsor statement_Licensed PFD","uuid":"371dd8b5-2c87-4c80-9079-f162c38a9781","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"na","systemVersion":"1"},{"title":"D4_RP-A501-0123_Patient facing documents KCCQ12_IT_Redacted","uuid":"2f34ba07-9c9e-47c6-ad38-9e0f3e6e7670","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"na","systemVersion":"1"},{"title":"D4_RP-A501-0123_PFD_Sponsor statement_Licensed PFD_IT","uuid":"3f8cf6a1-677b-4d81-837b-899499fa815a","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"na","systemVersion":"1"},{"title":"D1_RP-A501-0123_Protocol synopsis_ENG 2023-506480-34-00_Redacted","uuid":"6dab2f30-6bed-49e1-908f-ff33e395b88a","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"5.0","systemVersion":"6"},{"title":"D1_RP-A501-0123_Protocol synopsis_DE 2023-506480-34-00_Redacted","uuid":"019c8306-9476-4cd2-aae7-1484b00efd67","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"5.0","systemVersion":"6"},{"title":"D1_RP-A501-0123_Protocol synopsis layperson_DE 2023-506480-34-00","uuid":"1309b0b2-125f-4b9b-95a7-1d2a9c5845a4","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"2.1","systemVersion":"2"},{"title":"D1_RP-A501-0123_Protocol synopsis layperson_ENG 2023-506480-34-00","uuid":"b8ad0ead-e8d7-4cde-9bbf-9342d8b3d478","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"2.1","systemVersion":"2"},{"title":"D1_RP-A501-0123_Protocol synopsis_IT 2023-506480-34-00_Redacted","uuid":"7a1e5924-9ec2-400c-8996-7d285ea7fbd1","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"5.0","systemVersion":"4"},{"title":"D1_RP-A501-0123_Protocol synopsis layperson_IT 2023-506480-34-00","uuid":"2f76b9fc-a860-4e89-9405-1c840af1a81b","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":106176,"manualVersion":"2.3","systemVersion":"2"},{"title":"K1_RP-A5010123_IT_Recruitment arrangements_eng","uuid":"baa87bd2-16b1-4572-9ec1-4c2b26caba95","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"2.0","systemVersion":"2"},{"title":"K2_RP-A501-0123 _IT_Social Media and Search","uuid":"26ab3bbe-650e-4e10-a256-d956f5c5589e","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_RP-A501-0123 _IT_Patient Fact Sheet","uuid":"fde1b553-4dfe-4308-b813-7c03b742ac7d","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_RP-A501-0123 _IT_Patient Website","uuid":"b10aa2a3-aa8b-4dad-9b87-8a7a3db78cea","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_RP-A501-0123 _IT_Study-Specific Call Guide","uuid":"15a7484a-06b3-4651-91d3-4da9279a26c5","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_RP-A5010123_IT_Other subject info material_Primarius_App Setup_ita","uuid":"20797b0c-bfe0-4fac-8ece-c341edb90a82","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"3","systemVersion":"1"},{"title":"L2_RP-A501-0123_IT_Other subject info material_ PatientPrimary_Privacy Notice_ita","uuid":"80d8c29f-f89a-477e-a1e4-bc643427024c","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"2","systemVersion":"1"},{"title":"L2_RP-A501-0123_IT_Other subject info material_GP Letter_ita","uuid":"5aca46df-8904-442d-9c14-afd522bf0b84","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"1","systemVersion":"1"},{"title":"L2_RP-A501-0123_IT_Other subject info material_PatientPrimary_Payment Card Letter_ita","uuid":"26088756-ba39-4610-8310-c2e6be62ed2f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"1","systemVersion":"1"},{"title":"L2_RP-A501-0123_IT_Other subject info material_Primarius_ Screenshots_ita","uuid":"12f9d2e2-4e1b-416c-8878-327936684161","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"4.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_IT_Other subj info material_PatientPrimary_Expense Claim Form_ita_Redacted","uuid":"3a4ab4bd-2f57-4854-9e8b-3affcc1cb321","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_IT_Other subj info mat_PatientPrimary Personal Data Consent Form_ita","uuid":"6205511e-bb25-4c50-8479-2387be02429e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_IT_Other subj info mat_PatientPrimary_Patient Welcome Letter_ita","uuid":"68daf596-b4e7-4b5b-8086-f21a8b22b785","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_RP-A5010123_IT_SIS and ICF_Adult_ITA_Redacted","uuid":"ae12415b-b7d1-4a23-bddb-ef23f4b0c4da","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"3.2","systemVersion":"6"},{"title":"L1_RPA5010123_IT_SIS and ICF_Parent_ITA_Redacted","uuid":"9a9fa1c8-536a-4cd3-b3e2-bde6b5c3ed59","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"3.2","systemVersion":"6"},{"title":"L1_RPA5010123_IT_SIS and ICF_Assent 12-17_ITA_Redacted","uuid":"7ea416db-7b61-4b6a-85f1-708298377934","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"3.0","systemVersion":"3"},{"title":"L1_RPA5010123_IT_SIS and ICF_Assent 8-11_ITA_Redacted","uuid":"30025ce1-3c90-45da-affd-14543e80d5e9","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":327785,"manualVersion":"3.0","systemVersion":"4"},{"title":"K1_RP-A501-0123_ES_Recruitment arrangements","uuid":"087258ad-04f4-482e-b98a-d37e4e5cc5c6","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2 _RP-A501-0123_ES_Recruitment material_LAMPLIGHT_Patient Website","uuid":"4dac8031-36ad-45fc-9750-696be201c506","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2 _RP-A501-0123_ES_Recruitment material_LAMPLIGHT_Social Media and Search Ads","uuid":"babb1bc7-4b77-4766-b432-33aba20f0550","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2 _RP-A501-0123_ES_Recruitment material_LAMPLIGHT_Study Specific Call Guide","uuid":"4ee310fa-7b8b-4775-b06b-a38d6c934e3a","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2 _RP-A501-0123_ES_Recruitment material_Patient Fact Sheet","uuid":"f6fdcfb4-4f0a-4266-b1fc-daf50bd51a70","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_ES_Other subject information material_Primarius_App Setup Guide","uuid":"529b01c8-9f66-4560-81b3-62702de376f8","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"3.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_ES_Other subject information material_Primarius_App Screenshots","uuid":"71f186e3-9ea7-40cc-8f51-44d2c2369c60","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"4.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_ES_Other subject information material_PP_Expense Claim form","uuid":"980a9fc4-b524-40b9-a0c2-73bf15c165f5","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_ES_Other subject information material_PP_Privacy Notice","uuid":"87f639b2-f98c-45db-b629-4afefaaca69a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"2.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_ES_Other subject information material_PP_Personal Data Consent","uuid":"e4d5e0ff-7f2d-4710-92c9-1a04afa0eb6e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_ES_Other subject information material_PP_Payment Card Letter","uuid":"e3a22d60-de11-43c4-9a62-6079c5cfaf23","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_ES_Other subject information material_PP_Patient Welcome Letter","uuid":"fdb34c6f-3c53-469d-84c1-773c9e5776e0","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_RKET-RP-A501-0123_ES_SIS and ICF_Adult_Redacted","uuid":"ed3887f2-4e9e-4dcb-9bfb-b08b2c5fcd11","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"1.1","systemVersion":"2"},{"title":"L1_RP-A5RKET-01-0123_ES_SIS and ICF_Parent_Redacted","uuid":"4319f013-554f-4e45-9249-68cc8447ed17","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"1.1","systemVersion":"2"},{"title":"L1_RKET-RP-A501-0123_ES_SIS and Assent_12-17y_Redacted","uuid":"42f664f7-4ff1-439a-b246-d2b9568a6195","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"1.1","systemVersion":"2"},{"title":"L1_RKET-RP-A501-0123_ES_SIS and ICF_Pregnant Partner_Redacted","uuid":"a3e7bd64-f8e1-44b9-965e-aeb3792282fe","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":327846,"manualVersion":"1.1","systemVersion":"2"},{"title":"K1_RP-A501-0123_DE_Recruitment arrangements_eng","uuid":"284abd0d-f46d-489a-a7db-96345e9f846a","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"2.0","systemVersion":"2"},{"title":"K2_RP-A501-0123 _DE__Social Media and Search","uuid":"79ca6330-a012-4bce-a152-6df5ffbe2f90","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"1","systemVersion":"1"},{"title":"K2_RP-A501-0123 _DE_Patient Fact Sheet","uuid":"9661a7eb-0d01-425d-8fab-ebd1ecf6acf7","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"1","systemVersion":"1"},{"title":"K2_RP-A501-0123 _DE_Patient Website","uuid":"6485e3fd-8399-4c5b-9bf0-a80995c5d18a","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"1","systemVersion":"1"},{"title":"K2_RP-A501-0123 _DE_Study-Specific Call Guide","uuid":"96499752-19e8-4220-b199-22033b9098da","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"1","systemVersion":"1"},{"title":"L2_RP-A501-0123_DE_Other subj inf material_ PatientPrimary_Payment card_ger","uuid":"78391440-1ed9-42ea-8d45-35a0068135d0","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_DE_Other subj inf material_ PatientPrimary_Personal Data Consent Form_ger","uuid":"64378ab8-0fc2-40c8-9853-3a5f6fff18df","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_DE_Other subj inf material_ PatientPrimary_Welcome letter_ger","uuid":"769fed39-fb64-4278-b4ba-bbb5a2879b75","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_DE_Other subj inf material_PatientPrimary_Expense Claim Form_ger_Redacted","uuid":"5890ef6b-83d3-4629-bc73-0d198c451f13","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_DE_Other subj inf material_PatientPrimary_Privacy Notice_ger","uuid":"3fcbc7ee-9064-48fd-8363-d4ac0556fd68","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"2.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_DE_Other subj inf material_Primarius_App Setup_ger","uuid":"6a90c968-d8ac-4758-b591-7f37342072b1","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"3.0","systemVersion":"1"},{"title":"L2_RP-A501-0123_DE_Other subj inf material_Primarius_Screenshots_ger","uuid":"451f93a1-baad-409b-8b2b-d730cdad7349","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"4.0","systemVersion":"1"},{"title":"L1_RP-A501-0123_DE_SIS and ICF_Adult_ger_Redacted","uuid":"d7952239-167f-4681-9438-6466d9b6ba53","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"4.0","systemVersion":"6"},{"title":"L1_RP-A501-0123_DE_SIS and ICF_Assent 8-11_ger_Redacted","uuid":"c97b18d7-a8c9-412f-ad1f-2db6f0334e4f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"4.0","systemVersion":"4"},{"title":"L1_RP-A501-0123_DE_SIS and ICF_Assent 12-17_ger_Redacted","uuid":"d7751fd6-7b81-4157-8f79-3dfeedb9f7d4","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"4.0","systemVersion":"5"},{"title":"L1_RP-A501-0123_DE_SIS and ICF_Parent_ger_Redacted","uuid":"d470481d-f082-4fb5-b297-f4ed36cc1edc","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":29,"fileType":"PDF","associatedEntityId":343940,"manualVersion":"4.0","systemVersion":"6"}],"trialRegion":"Both","trialRegionCode":3,"correctiveMeasures":[]}